Q2 FY2026 · ended Jun 30, 2026 · Revenue $0, -100.0% YoY · Filed Jul 30, 2026
Crescent Biopharma, Inc. (CBIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $24.8 million. Free cash flow was -$19.5 million. As of Jun 30, 2026 it held $171.6 million in cash and investments and $1.4 million in total debt.
Revenue
$0
-100.0% vs prior quarter
Net income
$-24.84M
-14.0% vs year-ago quarter
Operating cash flow
$-19.46M
-18.7% vs year-ago quarter
Free cash flow
$-19.48M
-17.8% vs year-ago quarter
EPS
$-0.15
+6.3% vs prior quarter
Dividend per share
None
Shares outstanding
37.14M
+167.4% vs year-ago quarter
Net cash
$170.16M
Q2 FY2026
Operating margin
-2380.1%
Q1 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1253689
- Former names
- GLYCOMIMETICS INC (until Jun 23, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $1.0M | — | — | — |
| Operating income | -$26.4M | -$24.7M | -$91.5M | -$25.9M | -$21.0M |
| Net income | -$24.8M | -$23.3M | -$23.3M | -$24.6M | -$21.8M |
| Operating cash flow | -$19.5M | -$8.9M | -$26.7M | -$17.5M | -$16.4M |
| Free cash flow | -$19.5M | -$9.1M | -$26.9M | -$18.1M | -$16.5M |
| Total assets | $182.8M | $199.1M | $240.3M | $138.3M | $157.4M |
| Total liabilities | $19.5M | $15.3M | $37.3M | $21.6M | $18.2M |
| Stockholders' equity | $163.3M | $183.8M | $203.0M | $116.6M | $139.3M |
| Cash and investments | $171.6M | $189.2M | $213.2M | $133.3M | — |
| Total debt | $1.4M | $1.5M | $1.6M | $1.7M | $1.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 15, 2026 | Oct 15, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 15, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 14, 2026 | Jul 14, 2026 |
| 10-Q/A | Amended quarterly report | Jun 22, 2026 | Mar 31, 2026 |
All 676 Crescent Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.